Anika Therapeutics, Inc.
ANIK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | -0.01 | 0.06 | -1.07 |
| FCF Yield | -0.96% | -2.17% | -0.71% | 0.63% |
| EV / EBITDA | 70.40 | -25.67 | 20.68 | 192.25 |
| Quality | ||||
| ROIC | -8.98% | 0.34% | -4.73% | 1.39% |
| Gross Margin | 63.38% | 49.52% | 59.89% | 56.12% |
| Cash Conversion Ratio | -0.10 | 0.02 | -0.30 | 2.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.75% | -6.50% | -4.44% | 8.85% |
| Free Cash Flow Growth | 67.69% | -134.48% | -194.56% | -71.55% |
| Safety | ||||
| Net Debt / EBITDA | -9.83 | 3.90 | -3.05 | -31.90 |
| Interest Coverage | -2.18 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.84 | 1.37 | 1.58 | 1.80 |
| Cash Conversion Cycle | 223.04 | 309.51 | 259.67 | 233.42 |